Toronto, Ontario, Canada (PRWEB) February 22, 2010
Dalton Pharma Services announces the renewal of its Chemistry Services Agreement with Boehringer Ingelheim (Canada) Ltd. Under the agreement Dalton will continue to provide chemistry services in support of Boehringer's pharmaceutical development programs.
Peter Pekos, President of Dalton Pharma Services, said, “The extension of our long relationship with Boehringer Ingelheim (Canada) Ltd. aligns with Dalton’s vision to support the drug development programs of leading global pharma companies. Boehringer Ingelheim’s broad commitment to research in Canada despite the world wide reductions in the research sector, demonstrates the importance of Canada as a source of creative talent.”
About Dalton Pharma Services:
Dalton Chemical Laboratories Inc. o/a Dalton Pharma Services is a Health Canada approved contract pharmaceutical manufacturer that supplies chemistry, analytical and formulation development services to the biotechnology and pharmaceutical industries in the areas of chemistry, medicinal chemistry and fine chemical manufacture. Dalton provides cGMP manufacturing of solid dosage forms and sterile filling services to its customers at any stage of the regulatory process (Phase I, II, III or commercial). In its state of the art cGMP facilities, Dalton produces API at the gram or kilogram scale. Dalton conducts sterile fills to produce batches of finished drug product in vials or syringes, either aseptically filled or terminally sterilized, under fully validated conditions. In addition, Dalton’s analytical chemistry laboratory offers method development, validation and ICH stability programs to its clients.
Dalton Pharma Services
President & CEO